Key Highlights

  • USD 2.8 million raised through the at-the-market programme with H.C. Wainwright.
  • 437,869 American Depositary Shares sold, representing 52.5 million ordinary shares.
  • Cash runway extended to the fourth quarter of 2027, with shares outstanding now 210.3 million.

Addex Therapeutics (NASDAQ: ADXN) has raised USD 2.8 million through its at-the-market programme with H.C. Wainwright, selling 437,869 American Depositary Shares representing 52.5 million ordinary shares. The company stated the proceeds extend its cash runway to the fourth quarter of 2027. Shares outstanding have increased to 210.3 million.

How an at-the-market programme works

An at-the-market programme allows a company to sell new shares into the open market over time at prevailing prices through a designated agent, rather than raising Capital in a single marketed offering. It gives flexibility on timing and avoids the discount typically attached to a placement. The trade-off is that issuance occurs at whatever price the market is paying on the day.

The dilution arithmetic

The figures disclosed allow the scale to be measured. The 52.5 million new ordinary shares sit within a post-issue count of 210.3 million, which places the issuance at roughly 25 per cent of shares now outstanding and implies a pre-issue count near 157.8 million. On the ADS side, 52.5 million ordinary shares across 437,869 ADSs points to a ratio of about 120 ordinary shares per ADS, and USD 2.8 million across 437,869 ADSs implies an average of roughly USD 6.39 per ADS.

Stated plainly, the raise added about a quarter to the ordinary share count for USD 2.8 million. That is the figure a Shareholder is weighing against the runway extension to the fourth quarter of 2027.

What was not disclosed

The information reviewed did not state the period over which the sales took place, the remaining capacity under the at-the-market programme, the absolute cash balance behind the runway estimate, the assumptions supporting that estimate, or the intended use of proceeds. No detail was given on the pipeline spend the runway is expected to cover.

This article is general information only and does not take into account any individual objectives, financial situation or needs. It is not a recommendation to buy, sell or hold any security. All details are as stated in the company announcement or third party research referenced and are subject to change. Past performance is not a reliable indicator of future performance. Investors should consider the appropriateness of any information having regard to their own circumstances and seek independent financial advice before making any financial decision.